ClinicalTrials.govpublic full text
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
gastroesophageal adenocarcinoma, first line therapy, her2 + gastric cancer, pdl-1, metastases, gea, her2-positive, pd-l1 positive, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 912141
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.